Strides Pharma News and Updates

Name: Latest research reports of Strides Pharma Science Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Strides Pharma Science Ltd.
Rating: 4
Author: Geojit BNP Paribas

Keep track of all breaking news on Strides Pharma from all sources in a single place.

Strides Pharma Science Ltd.

11 Nov 2025

911.05

-2.90%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

Management remains optimistic about performance in other regulated markets, anticipating stronger revenue growth in FY26 as European partners prepare for product launches. The company also expects these markets to eventually generate...

Strides Pharma Science Ltd. is trading above all available SMAs

Strides Pharma Science Ltd.

31 Oct 2025

911.05

-2.90%

Strides Pharma Science Q2 net profit jumps 82% at 131.5 crore

Business Line

The company had posted a consolidated net profit of 72.3 crore in the corresponding period last fiscal, Strides Pharma Science said in a regulatory filing

Number of FII/FPI investors decreased from 287 to 275 in Sep 2025 qtr

Strides Pharma Q2FY26 results: Net profit jumps 82% to 131.5 crore

Business Standard | 31 Oct 2025 1 more

Strides Pharma Science Ltd.

18 Oct 2025

911.05

-2.90%

Strides Founder raises Rs 1000 crore to refinance debt

Economic Times

Arun Kumar, founder of Strides Group and OneSource, has secured 1,000 crore by pledging shares. This move refinances existing loans, extending maturities and simplifying repayments. The transaction aims to consolidate smaller borrowings into larger, long-term facilities. It reflects a broader effort to clean up the promoter's balance sheet and shows a decline in pledged shares, indicating deleveraging.

Promoters unpledged 5.97% of shares in last quarter. Total pledge stands at 44.13% of promoter holdings

Strides Pharma Science Ltd.

08 Oct 2025

911.05

-2.90%

ace turtle to revolutionise Indian denim market with exclusive G-STAR licensing deal

Business Line

The deal grants ace turtle exclusive rights to establish G-STAR's retail footprint through standalone outlets, shop-in-shop formats, and e-commerce.

Strides Pharma has gained 34.10% in the last 1 Year

Strides Pharma Science Ltd.

08 Sep 2025

911.05

-2.90%

Strides enters into product partnership with Kenox for nasal spray

Business Standard

Strides Pharma Science Ltd on Monday said its Singapore-based subsidiary has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc, which will strengthen the pipeline of nasal spray products across diverse therapeutic areas. Strides Pharma Global Pte, Singapore will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications, a joint statement said. The collaboration aims to accelerate affordable, high-quality medicines for patients in the US. However, it also mentioned that specific product details remain confidential at this stage. Kenox is a contract development and manufacturing company specialising in Orally Inhaled and Nasal Drug Products (OINDPs). Strides Pharma Science Executive Director Business Development Aditya Kumar said: "Weannounce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have...

Number of FII/FPI investors decreased from 287 to 275 in Sep 2025 qtr

Strides Pharma inks collaboration with Kenox for nasal spray portfolio in the US

Business Line | 08 Sep 2025

Strides Pharma Science Ltd.

14 Aug 2025

911.05

-2.90%

Strides towards Naya Bharat

Business Line

Strides Pharma Scien.. has an average target of 1085.00 from 1 broker.

Strides Pharma Science Ltd.

29 Jul 2025

911.05

-2.90%

Strides Pharma Science Results Earnings Call for Q1FY26

Conference Call with Strides Pharma Science Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Strides Pharma Science Ltd.

29 Jul 2025

911.05

-2.90%

Strides Pharma Profit Rises 81% To Rs 114 Crore In June Quarter

NDTV Profit

Revenue rose to Rs 1,120 crore for the June quarter against Rs 1,054 crore in the year-ago period, Strides Pharma Science said in a regulatory filing.